These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 17313619)

  • 1. Abatacept in the treatment of rheumatoid arthritis.
    Todd DJ; Costenbader KH; Weinblatt ME
    Int J Clin Pract; 2007 Mar; 61(3):494-500. PubMed ID: 17313619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD
    Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abatacept in biologic-naïve patients and TNF inadequate responders: clinical data in focus.
    Sherrer Y
    Curr Med Res Opin; 2008 Aug; 24(8):2283-94. PubMed ID: 18590608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
    Ruderman EM; Pope RM
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety profile of abatacept in rheumatoid arthritis: a review.
    Khraishi M; Russell A; Olszynski WP
    Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nursing guide to infusion therapy with abatacept for the treatment of rheumatoid arthritis.
    Barr C
    J Infus Nurs; 2007; 30(2):96-104; quiz 120. PubMed ID: 17413494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.
    Massarotti EM
    Clin Ther; 2008 Mar; 30(3):429-42. PubMed ID: 18405783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of abatacept in the management of rheumatoid arthritis.
    Nogid A; Pham DQ
    Clin Ther; 2006 Nov; 28(11):1764-78. PubMed ID: 17212998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abatacept: a novel treatment for moderate-to-severe rheumatoid arthritis.
    Reynolds J; Shojania K; Marra CA
    Pharmacotherapy; 2007 Dec; 27(12):1693-701. PubMed ID: 18041889
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
    Genovese MC; Becker JC; Schiff M; Luggen M; Sherrer Y; Kremer J; Birbara C; Box J; Natarajan K; Nuamah I; Li T; Aranda R; Hagerty DT; Dougados M
    N Engl J Med; 2005 Sep; 353(11):1114-23. PubMed ID: 16162882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abatacept as add-on therapy for rheumatoid arthritis.
    Allison C
    Issues Emerg Health Technol; 2005 Sep; (73):1-4. PubMed ID: 16317826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy.
    Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M
    J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abatacept: a biologic immune modulator for rheumatoid arthritis.
    Papagoras C; Drosos AA
    Expert Opin Biol Ther; 2011 Aug; 11(8):1113-29. PubMed ID: 21649536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [CTLA4-Ig (abatacept)].
    Harigai M
    Nihon Rinsho; 2007 Jul; 65(7):1231-7. PubMed ID: 17642237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.
    Westhovens R; Cole JC; Li T; Martin M; Maclean R; Lin P; Blaisdell B; Wallenstein GV; Aranda R; Sherrer Y
    Rheumatology (Oxford); 2006 Oct; 45(10):1238-46. PubMed ID: 16567357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy.
    Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M
    Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving patient outlook in rheumatoid arthritis: experience with abatacept.
    Coughlin M
    J Am Acad Nurse Pract; 2008 Oct; 20(10):486-95. PubMed ID: 19128344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis.
    Shergy WJ
    Semin Arthritis Rheum; 2009 Jun; 38(6):434-43. PubMed ID: 18538830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relative efficacies: antimalarials to abatacept - the choice is ours.
    Russell AS
    J Rheumatol Suppl; 2009 Jun; 82():17-24. PubMed ID: 19509326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.